An experimental drug that targets abnormally
high levels of a protein linked to cancer growth appears to
significantly reduce the proliferation
of prostate cancer cells in laboratory cell cultures and animals, while also making these cells considerably more vulnerable to
radiation, according to results
of a study led by Johns Hopkins scientists.